Vaxdyn Readies Vaccines To Target AMR Bacteria
First Spanish Biotech To Get CARB-X Funding
Emerging Company Profile: Multi-valent vaccine developer Vaxdyn has become the first Spanish biotech to be funded by CARB-X and will use the money to help fund a trivalent jab for use against the world’s three most dangerous drug-resistant bacteria.
You may also be interested in...
Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.
A surprise surge in Roche's R&D spending this year reflects high quality in-house innovation opportunities as well as high prices for external M&A targets, management said.
Roche unveiled a strong Q2 performance driven by new medicines and continued strong growth from its diagnostics division but analysts were most keen for clues on plans for gantenerumab, now in Phase III studies for Alzheimer’s disease.